I have no patience moving forward with a large firm standing on a sloppy book, trying to digest an acquisition it needs to make, but can only questionably afford.
Sometimes where there is smoke there is fire and other times not.
Here are few names that would make logical acquisition targets for larger players.
The Invesco S&P Spin-Off exchange-traded fund is holding its own against the SPDR S&P 500 ETF Trust. Can it keep it up?
Berkshire Hathaway's involvement and MoffettNathan's case are enough to consider buying in.
After a failed bid from the Franchise Group, the lack of a near-term buyout made Kohl's a good play for investors. Let's see how.
Musk's focus on the prevalence of spambot accounts really elucidated why TWTR is not a viable business.
Many fast-growing cloud software firms are now far from expensive, and both their business models and IT spending trends make them appealing targets.
Of course, as Elon Musk is a finite resource, Twitter's loss is Tesla's gain.
SGEN is a biotech with leadership precisely where big pharma wants to go.